COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PV-10 Chemoablation of Recurrent Breast Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00237354
Recruitment Status : Completed
First Posted : October 12, 2005
Last Update Posted : October 24, 2008
Information provided by:
Provectus Pharmaceuticals

Brief Summary:
The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of recurrent breast carcinoma. This study will also include a preliminary assessment of response of injected lesions by histologic assessment upon lesion excision at 1-3 weeks following IL PV-10 administration. Post-excision wound healing will be assessed clinically at 1 week and 4 weeks following excision of PV-10 injected lesions.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: PV-10 (rose bengal disodium 10%) Phase 1

Detailed Description:
This is a single center, open label, ascending dose study. Subjects with at least one recurrent, histologically confirmed measurable soft tissue breast carcinoma who are candidates for lumpectomy (removal of the lesion from the site of recurrence in the breast or at another site) or mastectomy will receive a single intralesional injection of PV-10 into a single target lesion to uniformly infiltrate the target lesion and up to a 0.5 cm margin at a dose of up to 1.0 mL/cc lesion volume. Systemic and locoregional adverse events will be monitored over the study interval. Subject accrual and PV-10 administration will be stopped if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4 hematological toxicity within a period of two weeks after PV-10 administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Safety and Tolerability Study of PV-10 Chemoablation of Recurrent Breast Carcinoma
Study Start Date : October 2005
Actual Primary Completion Date : June 2008
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Intervention Details:
  • Drug: PV-10 (rose bengal disodium 10%)
    PV-10 ablation of study lesion

Primary Outcome Measures :
  1. Systemic and locoregional adverse experience [ Time Frame: 5-7 weeks post dosing (4 weeks post excision) ]

Secondary Outcome Measures :
  1. Histopathologic response of PV-10 injected lesions [ Time Frame: 7-21 days post dosing ]
  2. Wound healing of PV-10 injected lesions [ Time Frame: 5-7 weeks post dosing (4 weeks post excision) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy confirmed recurrent soft tissue breast carcinoma
  • At least one measurable target lesion at least 0.5 cm and no more than 3 cm in longest diameter
  • Performance Status: Karnofsky 70-100% or ECOG 0-2
  • Life Expectancy: At least 6 months
  • Hematopoietic:

    • White blood cell count (WBC) at least 3000/mm3
    • Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)
    • Hemoglobin at least 10 g/dL
    • Platelet count at least 100,000/mm3
  • Coagulopathy: International Normalized Ratio (INR) at least 1.5.
  • Renal Function: Creatinine = 0.05-0.11 mmol/L
  • Hepatic Function:

    • Bilirubin = 3-21 umol/L
    • AST/ALT ≤ 3 times the upper limit of normal (ULN)
  • Cardiovascular Function: No major cardiovascular disease
  • Thyroid Function: T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum thyrotropin) within normal limits
  • Immunological Function: Adequate immune system function in the opinion of the investigator

Exclusion Criteria:

  • Radiation therapy to study lesions within 4 weeks
  • Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin)
  • Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment area within 4 weeks
  • Investigational agents within 4 weeks (or 5 half-lives)
  • Anti-tumor vaccine therapy within 12 weeks
  • Concurrent illness:

    • Severe diabetes or extremity complications due to diabetes
    • Significant concurrent disease or illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the investigator, compromise subject safety or compliance or interfere with interpretation of study results
    • Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated Graves' hyperthyroidism, or cystic fibrosis
  • Pregnancy or fertile female subjects who are not using effective contraception, or who are lactating
  • Known or suspected brain metastases or spinal cord compression.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00237354

Layout table for location information
New Zealand
Canterbury BreastCare
Christchurch, New Zealand
Sponsors and Collaborators
Provectus Pharmaceuticals
Layout table for investigator information
Study Director: Eric Wachter, Ph.D. Provectus Pharmaceuticals, Inc.
Principal Investigator: Chris Wynne, M.D. Oncology Service, Christchurch Hospital
Layout table for additonal information
Responsible Party: Eric Wachter, Ph.D., Provectus Pharmaceuticals, Inc. Identifier: NCT00237354    
Other Study ID Numbers: PV-10-BC-04
First Posted: October 12, 2005    Key Record Dates
Last Update Posted: October 24, 2008
Last Verified: October 2008
Keywords provided by Provectus Pharmaceuticals:
Recurrent soft tissue breast carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Breast Diseases
Skin Diseases